Doug Myers
Concepts (71)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ethics Committees | 1 | 2014 | 1 | 0.470 |
Why?
| Hospitals, Pediatric | 1 | 2014 | 187 | 0.410 |
Why?
| Immunity, Cellular | 2 | 2022 | 18 | 0.340 |
Why?
| Receptors, Antigen, T-Cell | 2 | 2019 | 7 | 0.330 |
Why?
| Adenoviridae | 1 | 2007 | 6 | 0.290 |
Why?
| Adenovirus Infections, Human | 1 | 2007 | 4 | 0.290 |
Why?
| DNA, Viral | 1 | 2007 | 13 | 0.290 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 50 | 0.270 |
Why?
| Salvage Therapy | 1 | 2019 | 6 | 0.170 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 7 | 0.170 |
Why?
| Neoplasm Recurrence, Local | 1 | 2019 | 31 | 0.170 |
Why?
| Drug Resistance, Neoplasm | 1 | 2019 | 26 | 0.170 |
Why?
| Humans | 8 | 2022 | 6896 | 0.160 |
Why?
| Quality of Life | 1 | 2019 | 140 | 0.160 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 66 | 0.150 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 52 | 0.150 |
Why?
| Adolescent | 5 | 2022 | 2197 | 0.140 |
Why?
| Dihydroxyacetone Phosphate | 1 | 2016 | 1 | 0.130 |
Why?
| Blood Chemical Analysis | 1 | 2016 | 4 | 0.130 |
Why?
| Erythrocytes | 1 | 2016 | 11 | 0.130 |
Why?
| Mass Spectrometry | 1 | 2016 | 18 | 0.130 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2016 | 40 | 0.130 |
Why?
| Child, Preschool | 4 | 2022 | 1569 | 0.130 |
Why?
| Adult | 3 | 2022 | 1181 | 0.130 |
Why?
| Child | 5 | 2022 | 3364 | 0.120 |
Why?
| Peer Review | 1 | 2014 | 2 | 0.120 |
Why?
| History, 20th Century | 1 | 2014 | 6 | 0.120 |
Why?
| History, 21st Century | 1 | 2014 | 6 | 0.120 |
Why?
| Referral and Consultation | 1 | 2014 | 32 | 0.110 |
Why?
| Young Adult | 3 | 2022 | 647 | 0.110 |
Why?
| Practice Guidelines as Topic | 1 | 2014 | 108 | 0.110 |
Why?
| Patient Simulation | 1 | 2013 | 2 | 0.110 |
Why?
| Prospective Studies | 2 | 2022 | 525 | 0.110 |
Why?
| Internship and Residency | 1 | 2013 | 39 | 0.110 |
Why?
| United States | 1 | 2014 | 669 | 0.100 |
Why?
| Pediatrics | 1 | 2013 | 186 | 0.090 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2008 | 1 | 0.080 |
Why?
| Recoverin | 1 | 2008 | 1 | 0.080 |
Why?
| Herpesvirus 4, Human | 1 | 2008 | 5 | 0.080 |
Why?
| Infusions, Intravenous | 2 | 2019 | 26 | 0.080 |
Why?
| Neuroblastoma | 1 | 2008 | 14 | 0.080 |
Why?
| Transplantation, Homologous | 1 | 2007 | 19 | 0.070 |
Why?
| Graft vs Host Disease | 1 | 2007 | 12 | 0.070 |
Why?
| T-Lymphocytes | 1 | 2007 | 31 | 0.070 |
Why?
| Feces | 1 | 2007 | 37 | 0.070 |
Why?
| Polymerase Chain Reaction | 1 | 2007 | 84 | 0.070 |
Why?
| Immunotherapy | 2 | 2019 | 16 | 0.060 |
Why?
| Male | 3 | 2019 | 3337 | 0.060 |
Why?
| Female | 3 | 2019 | 3525 | 0.060 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2022 | 15 | 0.050 |
Why?
| Immunity, Humoral | 1 | 2022 | 14 | 0.050 |
Why?
| Antibodies, Viral | 1 | 2022 | 47 | 0.050 |
Why?
| Vaccination | 1 | 2022 | 71 | 0.050 |
Why?
| Infant | 1 | 2007 | 1446 | 0.050 |
Why?
| Cell- and Tissue-Based Therapy | 1 | 2019 | 1 | 0.040 |
Why?
| Survival Rate | 1 | 2019 | 83 | 0.040 |
Why?
| Prognosis | 1 | 2019 | 211 | 0.040 |
Why?
| Follow-Up Studies | 1 | 2019 | 304 | 0.040 |
Why?
| Antigens, CD19 | 1 | 2018 | 1 | 0.040 |
Why?
| Remission Induction | 1 | 2018 | 24 | 0.040 |
Why?
| Survival Analysis | 1 | 2018 | 50 | 0.040 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 34 | 0.040 |
Why?
| Manikins | 1 | 2013 | 1 | 0.030 |
Why?
| Schools, Medical | 1 | 2013 | 1 | 0.030 |
Why?
| Truth Disclosure | 1 | 2013 | 3 | 0.030 |
Why?
| Neonatology | 1 | 2013 | 5 | 0.030 |
Why?
| Missouri | 1 | 2013 | 81 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2008 | 7 | 0.020 |
Why?
| Cell Proliferation | 1 | 2008 | 58 | 0.020 |
Why?
| Cell Line | 1 | 2008 | 81 | 0.020 |
Why?
| Phenotype | 1 | 2008 | 257 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|